VRCI

Verici Dx PLC

Health Care First-pass screen £7.19m

380/1000 Overall fit

AI beneficiary 35% 35

Operating leverage 25% 48

Valuation 25% 30

Downside protection 15% 40

First-pass take

Early-stage kidney transplant diagnostics with validated tests (Tutivia, PTRA) but pre-revenue-scale (334 tests FY2024). Net cash positive ($3.5m) but going concern warning to July 2025 without fundraise. Limited AI exposure; RNA/ML is methodology, not AI spending beneficiary. No valuation multiples in document.

Flags

going-concernloss-makingearly-stageno-valuation-datanot-ai-beneficiarycapital-dependentmicro-capcustomer-concentration